ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

No Thumbnail Available

Date

2019

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

http://hdl.handle.net/11727/4935

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar

Endorsement

Review

Supplemented By

Referenced By